Biodegradable Trans-Nasal Implant Bypassing Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Delivering therapeutic agents across the blood-brain barrier (BBB) to treat central nervous system (CNS) disorders is challenging due to the barrier's restrictive nature, particularly for biotherapeutics with high molecular size or charge, which limits the effectiveness of existing treatment methods.
Innovation Solution
A biodegradable trans-nasal drug delivery implant is developed, comprising a support body with a reservoir containing a polymer matrix and therapeutic agent, which is implanted in the nasal mucosa using a minimally invasive procedure, allowing for sustained release of therapeutic agents into the CNS by bypassing the BBB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery methods are used to administer therapeutic agents to the CNS, then the blood-brain barrier blocks the passage of biotherapeutics with high molecular size or charge, but this barrier protection prevents effective treatment of CNS disorders
Solution Approach 1:
The patent employs nasal mucosa as an intermediary delivery route that bypasses the blood-brain barrier. The implant is placed in the nasal cavity where therapeutic agents are delivered directly to the olfactory epithelium, allowing passage into the CNS through the olfactory nerve pathway rather than through the BBB, thus overcoming the barrier blockage while maintaining delivery effectiveness
Solution Approach 2:
The patent transitions from a systemic delivery approach (oral, intravenous) that must pass through the BBB to a direct trans-nasal approach that utilizes the olfactory pathway dimension. This dimensional change in delivery route allows therapeutic agents to reach the CNS without encountering the blood-brain barrier, resolving the contradiction between barrier protection and treatment effectiveness
2Reliability
If therapeutic agents are delivered systemically to treat CNS disorders, then the treatment can reach the CNS, but systemic side effects and immune responses increase
Solution Approach 1:
The patent segments the delivery system into a localized nasal implant that releases therapeutic agents directly at the olfactory epithelium. This segmentation confines the therapeutic action to the nasal-CNS interface pathway, preventing widespread systemic distribution and associated side effects while maintaining effective CNS treatment through the olfactory nerve route
Solution Approach 2:
The nasal mucosa serves as a localized intermediary that facilitates direct delivery to the CNS through the olfactory pathway. This intermediary route provides a targeted delivery mechanism that avoids the systemic circulation, thereby reducing immune responses and side effects while maintaining treatment effectiveness in the CNS
3Duration of action of moving object
If a biodegradable polymer implant is used for sustained release, then the duration of action is extended, but the polymer degradation products must be biocompatible and non-toxic
Solution Approach 1:
The patent selects and optimizes the molecular weight, composition, and degradation rate parameters of the biodegradable polymer to achieve sustained release over the required duration. By carefully controlling these parameters, the polymer degrades at a rate that matches therapeutic release requirements while producing biocompatible, non-toxic degradation products that do not harm the nasal tissue or induce immune responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implant enables prolonged and controlled delivery of therapeutic agents to the CNS, enhancing treatment efficacy for CNS disorders such as Parkinson's and Alzheimer's diseases while minimizing systemic side effects and immune response.
Implementation Method 1
the polymer matrix is a gel, such as an osmotic hydrogel that swells upon contact with a physiological fluid, such as extracellular fluid present in the nasal mucosa where the implant is placed. Osmotic swelling promotes the release of the therapeutic agent from the implant
Data Source
AI summary
A method of delivering a therapeutic agent into the central nervous system through the blood-brain barrier includes implanting an implant within the submucosal space of the olfactory epithelium. The implant can provide sustained drug delivery to the brain. The implant can be placed using a minimally invasive surgical approach.